Immune Monitor - November 2025

By SITC Communications posted 9 days ago
A Message from the President SITC’s 40 th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2025) marked a milestone for our society. We are deeply grateful to everyone who contributed to its success, including attendees, faculty, supporters, staff and volunteers. The meeting convened the immuno-oncology community in National Harbor, MD and virtually for several days of meaningful dialogue and groundbreaking science. With more than 1,300 abstracts presented, this year’s program demonstrated the continued momentum driving the field forward. Jennifer Wargo, MD, MMSc , delivered an excellent keynote address on the role of the ...
0 comments

Immune Monitor - October 2025

By SITC Communications posted 10-22-2025
A Message from the President I’m pleased to step in and provide this month’s update to the SITC community as we work through the temporary government shutdown together. While there is much to look forward to at SITC in the remainder of 2025, I am already looking ahead to the 2026 Spring Scientific program. This can’t-miss event will take place March 25–27, 2026, in Tucson, AZ, and virtually. The 2026 program will spotlight next-generation cellular therapies, T cell engagers, and novel combinations. Abstract submissions on these topics are now being accepted, and encore presentations are also welcome. Both poster and oral presentation ...
0 comments

Immune Monitor - September 2025

By SITC Communications posted 09-24-2025
A Message from the President In a little over a month, we will gather in a familiar place – the Gaylord National Resort and Convention Center in National Harbor, MD – for a milestone event: SITC’s 40 th Anniversary Annual Meeting & Pre-Conference Programs . I look forward to celebrating both our society and the incredible progress of our field with all of you. Anniversaries often bring a sense of reflection. For us as immuno-oncology scientists and clinicians, the road has not always been smooth, but together we’ve built something extraordinary, laying down the pathways and raising the structures that now define our field. ...
0 comments

Immune Monitor - August 2025

By SITC Communications posted 08-27-2025
A Message from the President While we weren’t sure exactly what this year would bring, one thing has been crystal clear — the future of cancer immunotherapy is bright, and it’s being shaped by the next generation of innovators. We’ve welcomed a surge of student members to the Society for Immunotherapy of Cancer (SITC) this year. In fact, student membership is up 20% compared to this time last year. The momentum is real and I’m so proud that SITC is a growing home for the next generation of the field. It’s not too late to join the SITC family and take advantage of member benefits this year! One of the most exciting opportunities now ...
0 comments

Immune Monitor - July 2025

By SITC Communications posted 07-30-2025
A Message from the President Over a year ago, SITC launched the bold #SITCQuestfor100 – a mission to accelerate the approval of 100 novel immuno-oncology (IO) agents over the next decade. We are convinced that groundbreaking, clinically meaningful IO innovations are on the horizon, with the potential to transform outcomes for patients worldwide. SITC is proud to be at the forefront of this effort, leading critical conversations, convening the scientific community, hosting impactful events and publishing forward-thinking research to drive the field forward. To this end, SITC recently hosted the 2025 NYSE Biotech Program , a sold-out event ...
0 comments

Immune Monitor - June 2025

By SITC Communications posted 06-24-2025
A Message from the President Every June, we honor Cancer Immunotherapy Month, an opportunity to highlight advancements, acknowledge future potential and celebrate the individuals driving innovation in cancer immunotherapy. While we celebrate the paradigm shift in cancer care our community pioneered, we still have much to do. The SITC leadership is committed to driving the science of biomarker discovery, optimizing patient selection in early phase clinical trials so that the right patient finds the right immunotherapy at the right time. Most recently, SITC published a commentary in the Journal for ImmunoTherapy of Cancer ( JITC ), “ ...
0 comments

Immune Monitor - May 2025

By SITC Communications posted 05-27-2025
A Message from the President Since SITC’s founding in 1985, the society has proudly supported the immuno-oncology (IO) community as the field has grown into a transformative standard of care for many cancer patients. As we celebrate our 40 th anniversary, we are thrilled to return to the Gaylord National Harbor Resort & Convention Center in National Harbor, MD, for the 40 th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2025) , taking place Nov. 5–9. This gathering will be a chance to reflect on the extraordinary progress our community has achieved over the past four decades, while also looking to the promising ...
0 comments

Immune Monitor - March 2025

By SITC Communications posted 03-28-2025
A Message from the President For 40 years, the Society for Immunotherapy of Cancer (SITC) has been dedicated to improving patient outcomes by advancing the science, development, and application of cancer immunotherapy. We achieve this through providing essential education, fostering global connections among professionals across all work settings, and serving as the leading voice in the cancer immunotherapy field. Recent federal actions are clearly having significant impacts on the fields of science and medicine. SITC is working closely with our trusted government consultant in Washington, DC to stay informed on the rapidly shifting ...
0 comments

Immune Monitor - February 2025

By SITC Communications posted 03-03-2025
A Message from the President During this period of significant change within the U.S. federal government, Dr. James Gulley temporarily stepped aside as President of the Society for Immunotherapy of Cancer (SITC). As Immediate Past President, I am honored to step in and assume his responsibilities until he is able to return. Despite the uncertainties that recent events have created, I am proud to say that SITC remains unwavering in its mission to develop potent immunotherapies for all cancer patients, and continues to deliver valuable immuno-oncology resources and events that support our members as they pursue cutting edge IO research, develop ...
0 comments

Immune Monitor - December 2024

By SITC Communications posted 12-23-2024
A Message from the President Over the last 12 months, you collectively dedicated your creativity, energy, and expertise to a set of incredibly strategic and impactful SITC initiatives. From implementing artificial intelligence into immuno-oncology (IO), to highlighting the current understanding of intralesional immunotherapies , to applying principles of glyco-immunology , the science we sought, challenged, and advanced this year was groundbreaking. Providing critical education on state-of-the-art drug development was top of mind for SITC in 2024. In September of this year, we hosted the SITC Immuno-Oncology Drug Summit to educate ...
0 comments

Immune Monitor - November 2024

By SITC Communications posted 11-22-2024
A Message from the President It's hard to believe SITC's 39 th Annual Meeting & Pre-Conference Programs is in the rearview mirror! A sincere thank you to all the attendees, supporters, organizers, faculty, staff and other volunteers who made our society's meeting a success. More than 5,000 professionals in the cancer research and medical community gathered in Houston and virtually to present and hear the latest data and research with more than 1,500 abstracts presented. I am so impressed and inspired by the remarkable science and research showcased at this year's meeting. We heard an outstanding Keynote Address from Rafi Ahmed, ...
0 comments

Immune Monitor - October 2024

By SITC Communications posted 10-23-2024
A Message from the President We are eagerly anticipating the 39 th Annual Meeting & Pre-Conference Programs , taking place Nov. 6–10 in Houston, TX and virtually. We saw a healthy number of abstracts submitted, over 1,500, and recently announced abstract titles and authors . While abstracts will highlight cutting-edge science from tumor immunology and cancer immunotherapy as a whole, standout categories for this year’s meeting are cellular therapies and biomarkers, immune monitoring and novel technologies. Additionally, we look forward to the upcoming announcement of Late-breaking Abstracts – Clinical Only (LBAs) titles and authors ...
0 comments

Immune Monitor - August/September 2024

By SITC Communications posted 09-10-2024
A Message from the President In three short weeks, SITC will host our first-ever IO Drug Development Summit in Boston . I’ve shared details on this new program in past Immune Monitors. Today, I’m eager to share thoughts from two of the organizers and longtime leaders in our field: Alexandra Snyder, MD of Generate Biomedicines and Jon M. Wiggington, MD of Bright Peak Therapeutics. Dr. Snyder, Dr. Wigginton and their fellow organizers were instrumental in planning the Summit. Dr. Snyder and Dr. Wigginton shared their perspective on why this summit is needed now more than ever. Dr. Wigginton, who was President of ...
0 comments

Immune Monitor - July 2024

By SITC Communications posted 07-25-2024
A Message from the President Last month, SITC launched a three-year strategic plan highlighting “global access and impact” as one of the six main strategic goals. This goal aims to collaborate strategically to expand the global reach of SITC resources and increase immuno-oncology access to diverse populations worldwide. A big part of this is elevating a rich oncology community through SITC’s diversity, equity, and inclusion (DEI) strategic plan . DEI isn’t a single initiative or program at SITC, it is a core value that is integrated into everything SITC does, led by a committee of dedicated volunteers. Most recently, ...
0 comments

Immune Monitor - June 2024

By SITC Communications posted 06-27-2024
A Message from the President Over the past decade, SITC played an instrumental role in establishing immunotherapy as a pillar of cancer therapy by promoting the translation of scientific innovation into treatment solutions for patients. Given the transformative clinical impact that cancer immunotherapy has already achieved, the SITC community is confident that the next decade will bring a new generation of highly innovative and effective immunotherapy agents to the patients who need them most. We recognize that there is still much work to be done. To that end, SITC is excited to introduce our three-year strategic plan , which serves as ...
0 comments

Immune Monitor - May 2024

By SITC Communications posted 05-24-2024
A Message from the President ust last week our community celebrated yet another novel immuno-oncology (IO) agent approval by the Food and Drug Administration (FDA) with tarlatamab-dlle, the first T-cell engager for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. This year alone, we’ve see three novel IO agents approved by the FDA, with two more PDUFA dates on the calendar before our 39 th Annual Meeting & Pre-Conference Programs (SITC 2024) taking place Nov. 6–10 in Houston, TX. We are already on our way to our goal of 100 new ...
0 comments

Immune Monitor - April 2024

By SITC Communications posted 04-26-2024
A Message from the President Immunotherapies have clearly transformed cancer treatments in recent years. However, the increased focus on developing more effective cancer immunotherapies has highlighted some of the biological, clinical, and regulatory hurdles in developing new immunotherapy agents. Collaborative efforts among regulators, preclinical researchers, clinical investigators, and industry stakeholders are essential to sustain the momentum in our field and ensure the prompt and appropriate clinical testing of innovative immunotherapies. To address the needs of the cancer immunotherapy community and streamline the immunotherapy drug ...
0 comments

Immune Monitor - March 2024

By SITC Communications posted 03-27-2024
A Message from the President Last month, we witnessed the monumental FDA approval of lifileucel, a first-in-class tumor infiltrating lymphocyte (TIL) therapy, for patients with unresectable or metastatic melanoma. Notably, the approval of lifileucel also marks the first approval of any cellular therapy for the treatment of solid tumors, thus significantly expanding its application beyond hematologic malignancies. This critical milestone event underscores the importance of supporting the biotech ecosystem to ensure promising novel immunotherapeutics have a pathway to approval for patients in need. The Society for Immunotherapy of Cancer ...
0 comments

Immune Monitor - February 2024

By SITC Communications posted 02-27-2024
A Message from the President It’s that time of year when the Society for Immunotherapy of Cancer (SITC) and the Forward Fund unveil their 2024 fellowship opportunities . Over $600,000 in funding is available to bolster the growth of early career investigators, nurturing the future cohort of experts in cancer immunotherapy. Since 2014, SITC has granted over $6 million in fellowships. I encourage you to take advantage of this chance to explore the available fellowships, whether you are eligible to apply or can share the opportunities with someone you know. Applications remain open until March 18. In addition to the annual ...
0 comments

Immune Monitor - January 2024

By SITC Communications posted 01-31-2024
A Message from the President Before we toast the start of 2024 together, let’s take a moment to celebrate all that our community achieved by reading the society’s 2023 Year in Review . While in San Diego for the SITC 2023 Annual Meeting & Pre-Conference Programs, SITC announced a goal to reach 100 new IO approvals in the next decade. As you enjoy the SITC 2023 Year in Review, you’ll be struck by the breadth and depth of our programming. I have no doubt that you will join me in doubling down on our commitment to reach that lofty goal. From our first Spring Scientific to the record-setting Annual Meeting, I’m confident this trip ...
0 comments